Treatment	Cause	Edge Weight	Shared Publications
COPD Treatment Cluster 12: Converging Pathways in Osteoarthritis and COPD for Chondroprotective Therapy Development	COPD Cause Cluster 28: Inflammatory Pathways Linking Osteoarthritis and COPD: Shared Mechanisms of Cartilage Destruction and Matrix Degradation	0.6653696498054474	171
COPD Treatment Cluster 12: Converging Pathways in Osteoarthritis and COPD for Chondroprotective Therapy Development	COPD Cause Cluster 25: Wound Healing Dysregulation and Tissue Remodeling as Systemic Influencers of COPD Pathogenesis	0.041666666666666664	12
COPD Treatment Cluster 12: Converging Pathways in Osteoarthritis and COPD for Chondroprotective Therapy Development	COPD Cause Cluster 8: Estrogen-Regulated Autophagy and miRNA Networks in Endometriosis-Related COPD Pathogenesis	0.02697495183044316	14
COPD Treatment Cluster 12: Converging Pathways in Osteoarthritis and COPD for Chondroprotective Therapy Development	COPD Cause Cluster 9: Joint Inflammation and Oxidative Stress as Contributing Factors to COPD Pathogenesis in Rheumatoid Arthritis Patients	0.019851116625310174	8
COPD Treatment Cluster 12: Converging Pathways in Osteoarthritis and COPD for Chondroprotective Therapy Development	COPD Cause Cluster 17: Eicosanoid Dysregulation and Cox Inhibition: Unveiling the Complex Links between COPD and Cardiovascular, Gastrointestinal, and Metabolic Disorders	0.018404907975460124	6
COPD Treatment Cluster 12: Converging Pathways in Osteoarthritis and COPD for Chondroprotective Therapy Development	COPD Cause Cluster 26: Epigenetic and Inflammatory Regulation of Oxidative Stress and Nitric Oxide Production in COPD Pathogenesis	0.016819571865443424	11
COPD Treatment Cluster 12: Converging Pathways in Osteoarthritis and COPD for Chondroprotective Therapy Development	COPD Cause Cluster 32: Autoimmune and Autoinflammatory Conditions as Indicators of COPD Risk and Disease Progression	0.010510510510510511	7
COPD Treatment Cluster 12: Converging Pathways in Osteoarthritis and COPD for Chondroprotective Therapy Development	COPD Cause Cluster 16: Unveiling Novel Targets and Immune Mechanisms in COPD Pathogenesis: From Muscle Metabolism to Macrophage Polarization	0.009985734664764621	7
COPD Treatment Cluster 12: Converging Pathways in Osteoarthritis and COPD for Chondroprotective Therapy Development	COPD Cause Cluster 18: Unraveling the Molecular Interplay of Î² Adrenoceptors, Gasotransmitters, and Sulfonation in COPD Pathogenesis	0.007952286282306162	4
COPD Treatment Cluster 12: Converging Pathways in Osteoarthritis and COPD for Chondroprotective Therapy Development	COPD Cause Cluster 23: Hormetic Regulation of Oxidative Stress and Inflammatory Pathways in COPD and Related Ischemic Diseases	0.00782472613458529	5
COPD Treatment Cluster 12: Converging Pathways in Osteoarthritis and COPD for Chondroprotective Therapy Development	COPD Cause Cluster 22: Periodontal Disease as a Source of Systemic Inflammation and COPD Exacerbation	0.006329113924050633	1
COPD Treatment Cluster 12: Converging Pathways in Osteoarthritis and COPD for Chondroprotective Therapy Development	COPD Cause Cluster 14: Psychological Stress and Neuroinflammatory Pathways in COPD Exacerbation and Progression	0.0055248618784530384	1
COPD Treatment Cluster 12: Converging Pathways in Osteoarthritis and COPD for Chondroprotective Therapy Development	COPD Cause Cluster 4: NLRP3 Inflammasome-Mediated Inflammatory Dysregulation in COPD Pathogenesis and Therapeutic Targets	0.005376344086021506	1
COPD Treatment Cluster 12: Converging Pathways in Osteoarthritis and COPD for Chondroprotective Therapy Development	COPD Cause Cluster 6: Intrauterine and Chronic Inflammation-Driven Dysregulation of Anti-Inflammatory Responses in COPD Development	0.004201680672268907	2
COPD Treatment Cluster 12: Converging Pathways in Osteoarthritis and COPD for Chondroprotective Therapy Development	COPD Cause Cluster 5: Environmental Toxicants and Cyclooxygenase Inhibition in Gastrointestinal COPD Pathways	0.003115264797507788	1
COPD Treatment Cluster 12: Converging Pathways in Osteoarthritis and COPD for Chondroprotective Therapy Development	COPD Cause Cluster 20: Lipid Dysregulation and Inflammation in Atherosclerosis-Related COPD Etiology and Progression	0.002881844380403458	1
COPD Treatment Cluster 12: Converging Pathways in Osteoarthritis and COPD for Chondroprotective Therapy Development	COPD Cause Cluster 38: Liver Damage, Inflammation, and Fibrogenesis as Systemic Consequences in COPD Pathogenesis	0.0028011204481792717	1
COPD Treatment Cluster 12: Converging Pathways in Osteoarthritis and COPD for Chondroprotective Therapy Development	COPD Cause Cluster 33: Gut Microbiota Dysbiosis and Intestinal Immune Homeostasis Disruption in COPD Pathogenesis	0.0024630541871921183	1
COPD Treatment Cluster 12: Converging Pathways in Osteoarthritis and COPD for Chondroprotective Therapy Development	COPD Cause Cluster 35: Cardiovascular and Metabolic Comorbidities as Modifiable Risk Factors for COPD Exacerbation	0.0021551724137931034	1
COPD Treatment Cluster 12: Converging Pathways in Osteoarthritis and COPD for Chondroprotective Therapy Development	COPD Cause Cluster 10: Natural Bioactive Polyphenols and Flavonoids as Potential Therapeutic Agents in COPD Prevention	0.0020920502092050207	1
COPD Treatment Cluster 12: Converging Pathways in Osteoarthritis and COPD for Chondroprotective Therapy Development	COPD Cause Cluster 11: Gut-Respiratory Axis: Inflammatory Disorders and Immune Dysregulation in COPD Pathogenesis	0.0018552875695732839	1
COPD Treatment Cluster 12: Converging Pathways in Osteoarthritis and COPD for Chondroprotective Therapy Development	COPD Cause Cluster 21: Neuroinflammatory Pathways in COPD: Intersection of Systemic Inflammation and Neurological Dysfunction	0.001447178002894356	1
